-
Exclusive: Aldeyra CEO Todd Brady Talks Drug Potential, Cash & New Talent
Thursday, June 2, 2016 - 4:01pm | 890Read More...Aldeyra Therapeutics Inc (NASDAQ: ALDX) is a micro-cap biotech company that specializes in the development of drugs for the treatment of immune and inflammatory diseases. Its most advanced drug is an eye drop treatment for Sjogren-Larsson Syndrome. Benzinga had the chance to sit down with...
-
Aldeyra CEO Todd Brady Explains Why He Thinks Company Can Have 'Dramatic' Impact In Healthcare
Wednesday, March 9, 2016 - 4:14pm | 1307Read More...Aldeyra Therapeutics Inc (NASDAQ: ALDX) is a small-cap biotech company that specializes in the development of drugs to treat immune and inflammatory diseases. Aldeyra’s most advanced drug is an eye drop treatment for Sjogren-Larsson Syndrome. Benzinga sat down with Aldeyra CEO Todd Brady to...
-
Aldeyra Therapeutics Surges 38%: Here's Why
Monday, February 29, 2016 - 12:11pm | 236Read More...Shares of Aldeyra Therapeutics Inc (NASDAQ: ALDX), a nano-cap biotechnology company, surged higher by more than 38 percent Monday morning after the company reported positive results from a Phase IIa clinical trial. Aldeyra Therapeutics reported that the results from a randomized, parallel-group...
-
Exclusive: CEO Todd Brady Lays Out Aldeyra's Groundbreaking Development
Tuesday, June 17, 2014 - 3:57pm | 435Read More...In an interview with Benzinga, Aldeyra Therapeutics (NASDAQ: ALDX) CEO Dr. Todd Brady discussed his company’s opportunities. “What we have is an aldehyde trap,” began Brady. “We developed molecules that bind to and dispose of aldehyde.” Aldehydes are an agent in...
